Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA FE 1 20 versus DEMULEN 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA FE 1 20 versus DEMULEN 1 35 21.
AUROVELA FE 1/20 vs DEMULEN 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. Inhibits ovulation by suppressing gonadotropin release (FSH, LH). Increases viscosity of cervical mucus, reducing sperm penetration. Alters endometrial lining to reduce implantation likelihood.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and ethynodiol diacetate (progestin). Inhibits gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, suppressing ovulation. Additionally, thickens cervical mucus and alters endometrial receptivity.
One tablet (1 mg norethindrone acetate, 20 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by one iron tablet (75 mg ferrous fumarate) orally once daily for 7 days.
One tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol.
None Documented
None Documented
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours (with interindividual variability).
Ethinyl estradiol: 13±3 hours (terminal); norethindrone: 8±3 hours. Steady-state achieved after ~5 days.
Renal: ~50-60% as metabolites; fecal: ~40-50% as metabolites; biliary excretion contributes to fecal elimination.
Renal (primarily as glucuronide and sulfate conjugates): ~60%; fecal: ~40%
Category C
Category C
Oral Contraceptive
Oral Contraceptive